# Cansativa

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cansativa

- Industry: Pharmaceuticals
- Headquarters: Germany
- Website: www.cansativa-group.de
- Total disclosed funding: $15M
- Latest round: Series B (Feb 16, 2022)
- Investors on record: 3

## About

Based in Germany and founded in 2017, Cansativa GmbH operates as a medical cannabis distributor. Benedikt Sons and Jakob Sons are the co-founders and serve as co-CEOs of the company as of 2021. In February 2022, Cansativa GmbH raised EUR 13 million in series B funding led by new investor Casa Verde Capital, LLC, with participation from other new investors Alluti GmbH and Argonautic Ventures.

The company serves as a one-stop-shop for medical cannabis. It is involved in every step of the value chain, from importing goods to selling them to thousands of pharmacies, as well as all logistics. The Cansativa Group provides accessories and other items to pharmacies across Germany in addition to cannabis blossoms and medicinal cannabis products. Furthermore, Cansativa provides a platform for all areas of market access, cannabis distribution, contract logistics, and packaging services.

The company plans to use the series B funding to expand its medical cannabis product portfolio and build out its recreational platform ahead of legalization in Germany.

## Funding rounds

- Series B, Feb 16, 2022, $15M — Casa Verde Capital, Argonautic Ventures, Alluti

## Investors

- Casa Verde Capital (https://capitalatlas.ai/funds/casa-verde-capital) — Series B
- Argonautic Ventures (https://capitalatlas.ai/funds/argonautic-ventures) — Series B
- Alluti — Series B